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Interstage mortality after the Norwood procedure: Results of the
multicenter Single Ventricle Reconstruction trial
Nancy S. Ghanayem, MD,a Kerstin R. Allen,b Sarah Tabbutt, MD, PhD,c Andrew M. Atz, MD,d
Martha L. Clabby, MD,e David S. Cooper, MD,f Pirooz Eghtesady, MD,g Peter C. Frommelt, MD,a
Peter J. Gruber, MD,c Kevin D. Hill, MD,h Jonathan R. Kaltman, MD,i Peter C. Laussen, MBBS,j
Alan B. Lewis, MD,k Karen J. Lurito, MD,l L. LuAnn Minich, MD,m Richard G. Ohye, MD,n
Julie V. Schonbeck,b Steven M. Schwartz, MD,o Rakesh K. Singh, MD,p and Caren S. Goldberg, MD,n for
the Pediatric Heart Network Investigators
Objective: For infants with single ventricle malformations undergoing staged repair, interstage mortality is reported at 2% to 20%. The Single Ventricle Reconstruction trial randomized subjects with a single morphologic
right ventricle undergoing a Norwood procedure to a modified Blalock–Taussig shunt (MBTS) or a right
ventricle-to-pulmonary artery shunt (RVPAS). The aim of this analysis was to explore the associations of interstage mortality and shunt type, and demographic, anatomic, and perioperative factors.

CHD

Methods: Participants in the Single Ventricle Reconstruction trial who survived to discharge after the Norwood
procedure were included (n ¼ 426). Interstage mortality was defined as death postdischarge after the Norwood
procedure and before the stage II procedure. Univariate analysis and multivariable logistic regression were
performed adjusting for site.
Results: Overall interstage mortality was 50 of 426 (12%)—13 of 225 (6%) for RVPAS and 37 of 201 (18%)
for MBTS (odds ratio [OR] for MBTS, 3.4; P<.001). When moderate to severe postoperative atrioventricular
valve regurgitation (AVVR) was present, interstage mortality was similar between shunt types. Interstage mortality was independently associated with gestational age less than 37 weeks (OR, 3.9; P ¼ .008), Hispanic ethnicity (OR, 2.6; P ¼ .04), aortic atresia/mitral atresia (OR, 2.3; P ¼ .03), greater number of post-Norwood
complications (OR, 1.2; P ¼ .006), census block poverty level (P ¼ .003), and MBTS in subjects with no or
mild postoperative AVVR (OR, 9.7; P <.001).
Conclusions: Interstage mortality remains high at 12% and is increased with the MBTS compared with the RVPAS
if postoperative AVVR is absent or mild. Preterm delivery, anatomic, and socioeconomic factors are also important.
Avoiding preterm delivery when possible and close surveillance after Norwood hospitalization for infants with
identified risk factors may reduce interstage mortality. (J Thorac Cardiovasc Surg 2012;144:896-906)
Earn CME credits at
http://cme.ctsnetjournals.org

Survivors of the Norwood procedure for hypoplastic left
heart syndrome (HLHS) and other single right ventricle
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anomalies are left with the combination of an inefficient
parallel circulation with volume load to the systemic ventricle, potential inferior pumping capability of a systemic
right ventricle, and risk of compromise of the systemic to
pulmonary artery shunt. These factors expose patients to
a heightened risk for circulatory collapse. This inherently
fragile physiology persists to the stage II procedure when
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Kerstin R. Allen’s current affiliation is Infinity Pharmaceuticals, Boston, Mass; Sarah
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the parallel circulation is eliminated through takedown of
the systemic to pulmonary artery shunt and creation of
a cavopulmonary connection. Mortality postdischarge after
the Norwood hospitalization and before the stage II procedure (interstage period) is reported to be 2% to 20%.1-4
Specific risks associated with interstage mortality identified in various investigations include a diminutive ascending aorta as seen in aortic atresia, the presence of
a restrictive atrial communication, postoperative arch obstruction, obstructed shunt flow, pulmonary artery distortion, and atrioventricular valve regurgitation (AVVR).5,6
Age at surgery, postoperative arrhythmias, airway
complications, feeding difficulties, and noncardiac disease
processes such as gastroenteritis or upper respiratory
infection also have been implicated.3,4 Compared with the
right ventricle-to-pulmonary artery shunt (RVPAS), higher
interstage mortality has been reported for the modified Blalock–Taussig shunt (MBTS).7,8
The National Heart, Lung, and Blood Institute–sponsored Pediatric Heart Network Single Ventricle Reconstruction (SVR) trial includes the largest prospective cohort of
infants with HLHS or related single right ventricle anomalies with longitudinal follow-up after the Norwood procedure. The primary results of the SVR trial demonstrated
improved transplant-free survival at 12 months in those randomized to receive an RVPAS at the Norwood procedure
compared with those randomized to the MBTS. Although
interstage survival was not specifically reported, the highest
incidence of transplant or death occurred between 30 days
after the Norwood procedure and the stage II procedure.9
The goal of this analysis was to determine anatomic,
surgical, and additional patient-related risk factors for interstage mortality postdischarge after the Norwood procedure
and before the stage II procedure in this unique cohort. We
specifically hypothesized that infants palliated with an

MATERIALS AND METHODS
The Pediatric Heart Network SVR trial compared outcomes between
subjects randomized to RVPAS and subjects randomized to MBTS at the
time of the Norwood procedure. Details of the trial design have been reported.10 The institutional review board or research ethics board at each
participating center approved the study protocol, and written informed consent was obtained from parents before trial enrollment.

Study Sample
Subjects randomized in the multicenter SVR trial who survived to discharge from the hospital after the Norwood procedure are included in this
analysis. Twenty-two subjects surviving the Norwood procedure, but not
discharged before the stage II procedure, were excluded from the primary
analysis because of limitations in distinguishing Norwood operative mortality from interstage mortality for subjects with planned inpatient care
to stage II procedure. Two subjects whose dates of stage II procedure could
not be determined and 2 subjects whose stage II procedures were performed uncharacteristically late (ie, >14 months of age) were excluded
from the primary analysis.

Study Design and Measurements
Shunt type was defined for this analysis as the shunt in place at the end
of the Norwood procedure. The surgeon had the option to modify the shunt
if anatomy was encountered that made the randomized shunt assignment
not feasible. Other than random assignment of shunt, all participants
were managed according to the standard practices at their clinical centers.
A list of all variables that were recorded and analyzed is included in Appendix Table 2. In brief, before the Norwood procedure, a detailed preoperative
medical history was recorded, including demographics, patient characteristics, and anatomic diagnosis. Operative variables included shunt type,
pharmacologic strategies, perfusion method, and additional cardiac operations. The perfusion method during circulatory support was classified into
1 of 3 categories: deep hypothermic circulatory arrest (DHCA), regional
cerebral perfusion with DHCA time of 10 minutes or less, or regional
cerebral perfusion with DHCA time greater than 10 minutes. Postoperative
data recorded for the Norwood hospitalization included procedures, serious
adverse events such as cardiopulmonary resuscitation (CPR) and use of
extracorporeal membrane oxygenation (ECMO), number of previously
described complications,11 hospital length of stay, and feeding methods
at discharge after the Norwood procedure.
Echocardiograms were obtained before and after the Norwood procedure. The echocardiograms were interpreted centrally at a core laboratory
(Medical College of Wisconsin) to assess the degree of AVVR (none/mild
vs moderate/severe), to measure right ventricular end-systolic volume
(RVESV) and right ventricular end-diastolic volume (RVEDV), and to
determine fractional area change and right ventricular ejection fraction
(RVEF). The primary measure of right ventricular contractility used in
the multivariable model was right ventricular fractional area change,
because the other measures of systolic function including RVEF, RVESV,
and RVEDV could not be obtained for 23% of the subjects. In the 330 subjects for whom both measurements were available, there was a high degree
of correlation (R ¼ 0.89) between the RVEF and the right ventricular fractional area change.
A subgroup of subjects consented for evaluation by a geneticist. Genetic
evaluations performed for clinical indications were also recorded. Subjects
were classified as to whether a specific genetic syndrome was identified and
whether ‘‘other abnormalities’’ (ie, not identified with a syndrome) were
present.
Socioeconomic status at the time of randomization was assigned using
a US census–based score derived from 6 measures based on income, housing, and occupational-related features of the subject’s census block tract, as
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Abbreviations and Acronyms
AVVR ¼ atrioventricular valve regurgitation
BSA
¼ body surface area
CPR
¼ cardiopulmonary resuscitation
DHCA ¼ deep hypothermic circulatory arrest
ECMO ¼ extracorporeal membrane oxygenation
HLHS ¼ hypoplastic left heart syndrome
MBTS ¼ modified Blalock–Taussig shunt
OR
¼ odds ratio
RVEDV ¼ right ventricular end-diastolic volume
RVEF ¼ right ventricular ejection fraction
RVESV ¼ right ventricular end-systolic volume
RVPAS ¼ right ventricle-to-pulmonary artery
shunt
SVR
¼ Single Ventricle Reconstruction

MBTS would be at increased risk of interstage death compared with those palliated with an RVPAS.
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TABLE 1. Associations of interstage death, site adjusted

Variables
Site
Shunt

Demographic characteristics
Hispanic

US census % below poverty level
Tertiles

CHD

US census socioeconomic score
Baseline characteristics
Gestational age (wk)
Preterm (gestational age < 37 wk)

Interstage deaths
(N ¼ 50)
–
50
13 (26)
37 (74)

14
1

RVPAS
MBTS

–
376
212 (56)
164 (44)
371
305 (82)
66 (18)

50
33 (66)
17 (34)

1

No
Yes

364
131 (36)
113 (31)
120 (33)
0.32  5.1

45
5 (11)
23 (51)
17 (38)
1.4  4.4

2
–
–
–
1

38.3  1.5
376
344 (91)
32 (9)
3.2 (0.5)
376
235 (62)
141 (38)

37.7  1.9
50
40 (80)
10 (20)
3.0 (0.5)
50
26 (52)
24 (48)

1
1

5.6  3.7
28.9  19.0
373
211 (57)
91 (24)
71 (19)

6.5  5.1
36.2  33.3
49
28 (57)
8 (16)
13 (27)

1
1
2

2.08  2.1
4.9  1.7

3.58  3.4
5.6  2.2

1
1

376
71 (19)
305 (81)
376
47 (13)
24 (6)
19 (5)
159 (42)
127 (34)

50
20 (40)
30 (60)
50
8 (16)
12 (24)
2 (4)
15 (30)
13 (26)

1

370
333 (90)
37 (10)

47
35 (74)
12 (26)

1

None/mild
Moderate/severe

368
172 (47)
196 (53)

46
30 (65)
16 (35)

1

<0.3 cm
0.3 cm

n

Responses

426
426

–

421

409
–
–
–
409

–
<5.42%
5.42%-13%
13%

426
426
37 wk
<37 wk

Birth weight (kg)
AA/MA

426
426
No
Yes

Norwood hospitalization
Age at Norwood (d)
Norwood length of stay (d)
Perfusion strategy
DHCA only
RCP only or RCP/DHCA time  10 min
RCP and DHCA time > 10 min
Complications and serious adverse events during
Norwood hospitalization
No. of complications post-Norwood
No. of medications at discharge
Feeding status at discharge post-Norwood
Any oral feeding

426
426
422

426
426
426
No
Yes

Feeding category (4 df)
No oral, G or GJ tube
No oral, NG or NJ tube
Oral and G or GJ tube
Oral and NG or NJ tube
Only oral
Echocardiography pre-Norwood
AVVR

Ascending aorta diameter (R301), cm
pre-Norwood
Median cutoff

Site adjusted

Interstage survivals
(N ¼ 376)

426

417

df

OR

P
<.001

3.44
.07
–
1.99

1
1

.006
0.38
1.73
–
0.95
0.80
–
2.81
0.57

.13
.02
.01

.05
.20

–
1.49
1.06
1.01

.11
.03
.19

0.34
0.38
–

1.22
1.15

<.001
.098
<.001

–
0.28
<.001

4
1.68
8.40
1.52
0.88
–

.004
–
3.15

414
414

.008
2.44
–
(Continued)
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TABLE 1. Continued

n

Echocardiography post-Norwood
RV end-diastolic volume/BSA1.3 (mL/m2.6)
RV end-systolic volume/BSA1.3 (mL/m2.6)
RVEF (%)
RV fractional area change (%)
AVVR grade

Responses

330
330
330
409
423
None/mild
Moderate/severe

Reversal of pulmonary vein flow

384
No
Yes

Interstage deaths
(N ¼ 50)

91.2  25.2
48.7  17.0
47.3  8.0
37.0  7.7
374
297 (80)
77 (20)
337
285 (85)
52 (15)

98.3  32.8
56.6  23.2
43.2  7.3
34.9  6.8
49
32 (65)
17 (35)
47
44 (94)
3 (5)

Interaction
Atrioventricular valve insufficiency by shunt
None/mild

Site adjusted
df

OR

P

1
1
1
1
1

1.01
1.02
0.94
0.97

.14
.03
.01
.12
.06

–
1.87
1

.18
–
0.46

1

.009

MBTS
RVPAS

126 (82)
171 (97)

27 (18)
5 (3)

6.71

<.001

MBTS
RVPAS

37 (80)
40 (83)

9 (20)
8 (17)

1.04

.94

Moderate/severe

Analyses were performed using logistic regression. Frequency and percent are provided for categoric variables; mean and standard deviations are presented for continuous variables. Firth’s adjustment was used if the model fit was questionable. Discharge feeding categories were excluded from the model in favor of any oral feeding at discharge. Only
associations with a P<.20 are included in the table. For the interaction term, the ORs and P values of shunt type by atrioventricular valve insufficiency are provided. df, Degrees of
freedom; OR, odds ratio; RVPAS, right ventricle-to-pulmonary artery shunt; MBTS, modified Blalock–Taussig shunt; AA/MA, aortic atresia/mitral atresia; DHCA, deep hypothermic circulatory arrest; RCP, regional cerebral perfusion; G, gastrostomy, GJ, gastric-jejunal; NG, nasogastric; NJ, nasojejunal; AVVR, atrioventricular valve repair; RV, right ventricle; BSA, body surface area; RVEF, right ventricular ejection fraction.

well as a score measuring the percent below the poverty level in the subject’s census block tract.12

Statistical Methods
Descriptive statistics presented include median with interquartile range
for skewed variables, mean and standard deviation for other continuous variables, and frequency with percentage for categoric variables. Tertiles of
continuous measures were fit to determine whether the association between
predictor and outcome was nonlinear. Dichotomies were also explored.
Univariate logistic regression and logistic regression adjusted for site
were used to obtain initial estimates of association between interstage survival and each candidate predictor. Predictors significant at P less than .20
at the univariate or site-adjusted level were included in the multivariable
modeling. Multivariable models were developed using stepwise logistic regression with bootstrap bagging 1000 samples to determine the reliability
of each individual predictor. The small number of events made the bootstrapping procedure unstable when site (14 degrees of freedom) was a candidate predictor; thus, the annual center volume of screened patients with
a single right ventricle and planned Norwood procedure was included as
a surrogate for site in bootstrapping models. A predictor was retained in
the final site-adjusted multivariable model if bootstrapping reliability
was greater than 45% and its P value was less than .05.
To determine whether some prespecified factors had differential associations dependent on shunt type, interaction terms were explored. Specifically, interactions of shunt type with birth weight (<2.5 vs 2.5 kg), low
gestational age (<37 weeks), ethnicity, obstructed pulmonary venous return, presence of aortic atresia, pre-Norwood and post-Norwood AVVR,
and ECMO or CPR during the Norwood hospitalization were examined
for their association with interstage death or transplant. After the multivariable model main effects were determined, the significant interactions were
added and retained if significant at a P value less than .05.

In an exploratory analysis, the multivariable model was developed using
the same approach, but after imputing missing values of RVEF, RVESV indexed to body surface area (BSA)1.3, and RVEDV indexed to BSA1.3. Simple regression imputation was used for RVEF, which had 23% of the data
missing at random. Right ventricular fractional area change was used to predict RVEF. For 17 subjects (4%) who were missing both measurements and
for subjects missing RVESV or RVEDV, mean imputation was used. These
imputed predictors were included in the model selection process. All analyses were conducted using SAS version 9.2 (SAS Institute, Inc, Cary, NC).

RESULTS
Study Sample
Of the 549 subjects who were randomized in the SVR
trial and underwent the Norwood procedure, 97 died
(88) or underwent heart transplantation (9) during the Norwood hospitalization, 22 remained as inpatients until the
stage II procedure, and 430 were discharged before the
stage II procedure (Figure 1). The 22 subjects who survived the Norwood procedure and were not discharged before the stage II procedure differed from those who were
discharged before the stage II procedure in that hospitalized subjects had a higher rate of ECMO, CPR, moderate
or greater AVVR, and postoperative complications (Appendix Table 3). Four subjects discharged were excluded
from the analysis because of an uncharacteristically late
stage II procedure (n ¼ 2) or unknown timing of the stage
II procedure (n ¼ 2). The remaining 426 subjects were
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FIGURE 1. Subject participation status from randomization through the interstage period. A total of 430 subjects were discharged after the Norwood
procedure. Four of these subjects were excluded because of an unusually late or missing date of the stage II procedure.

discharged after the Norwood procedure and formed the
analytic cohort. No subject discharged after the Norwood
procedure underwent heart transplantation before the stage
II procedure.

Interstage Survival
Of the 426 interstage subjects, 376 (88%) survived to the
stage II procedure. Interstage survival was higher in subjects who received the RVPAS (212/225; 94%) compared

TABLE 2. Multivariable model of predictors of interstage mortality with site adjustment: N ¼ 399 (adjusted R2 ¼ 0.35)
Died/heart transplant?

Odds ratio
(95% CI)

Model
P value

–

–
–

.823
.03

117 (84)
165 (97)

23 (16)
5 (2.9)

9.7 (3.1-30.3)
–

Contrast <.001

33 (79)
39 (83)

9 (21)
8 (17)

1.4 (0.4-5.0)

Contrast .57

30 (75)
324 (90)

10 (25)
35 (10)

3.9 (1.4-10.8)

.008

63 (79)
291 (91)

17 (21)
28 (8.7)

2.6 (1.1-6.5)

.04

134 (85)
220 (91)

23 (15)
22 (9.1)

2.3 (1.1-5.0)

.03

2.0  2.0

3.2  3.3

1.2 (1.1-1.4)

128 (96)
109 (83)
117 (87)

5 (4)
23 (17)
17 (13)

0.38 (0.12-1.3)
2.5 (1.02-6.0)
–

.006
.003
.15 (0.05-0.48)*
–

Predictor

No

Yes

Site
AVVR grade by shunt
None/mild
MBTS
RVPAS
Moderate/severe
MBTS
RVPAS
Low gestational age (<37 wk)
Yes
No
Hispanic
Yes
No
AA/MA
Yes
No
No. of complications post-Norwood and predischarge
Mean  SD
US Census percentage below poverty level tertiles
<5.42
5.42-13.0
13.0

–

Site 19 was excluded from this analysis because all 3 subjects from this site survived and render the model unstable. CI, Confidence interval; AVVR, atrioventricular valve repair;
MBTS, modified Blalock–Taussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt; AA/MA, aortic atresia/mitral atresia; SD, standard deviation. *Odds of mortality/transplant among subjects in the < 5.42 tertile compared with subjects in the 5.42-13.0 tertile.
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FIGURE 2. Kaplan–Meier plot of interstage survival by shunt type: Interstage survival, defined as percentage alive postdischarge after the Norwood
procedure and before the stage II surgery, was significantly better for subjects with an RVPAS than for subjects with an MBTS. MBTS, Modified
Blalock–Taussig shunt; RVPAS, right ventricle-to-pulmonary artery shunt.

with those who received the MBTS (164/201; 82%). The
odds ratio (OR) for interstage mortality for the MBTS versus the RVPAS was 3.4 (95% confidence interval, 1.8-6.6;
P<.001) (Figure 2). Of the subjects who died during the interstage period, the mean time to death postdischarge after
the Norwood procedure was earlier in the MBTS group (1.7
 1.6 months vs 2.8  1.5 months postdischarge after the
Norwood procedure, P <.001), with a mean age at death
3.0  2.0 months in the MBTS group and 4.3  1.7 months
in the RVPAS group (P ¼ .01). The stage II procedure was
performed at similar ages for the 2 shunt types (5.5  1.7
months vs 5.3  1.6 months, P ¼ .34).
Risk Factors for Interstage Mortality
Univariate analysis. Univariate analysis was performed to
assess the association of each potential risk factor with interstage mortality (Table 1). In addition to the MBTS, younger gestational age, census tract block with 5.4% to 13% of
inhabitants below federal poverty level, ascending aorta diameter less than 3 mm, longer Norwood hospital length of
stay (median, 25; interquartile range, 17 to 44 days vs 23
days; interquartile range, 16-36), greater number of postoperative complications, and failure to feed orally before hospital discharge were associated with interstage mortality.
The risk of interstage mortality was also higher in subjects
without any oral feeding with a nasal enteral tube compared
with a gastrostomy tube (OR, 5.0; 95% confidence interval,
1.5-17.1; P ¼ .01). Moderate to severe postoperative
AVVR, lower RVEF, and greater RVESV indexed to

BSA1.3 measured on post-Norwood echocardiograms (performed 15  10 days after the Norwood procedure) were
each associated with interstage mortality. Site was not a significant predictor of interstage mortality (P ¼ .16). Genetic
syndrome and nonsyndromic comorbidities also were not
associated with interstage mortality.
Of the prespecified factors, only the interaction of shunt
type and postoperative AVVR was significantly associated
with interstage mortality (P ¼ .009). After adjustment for
site, the influence of shunt type varied with degree of
AVVR. In subjects with postoperative none/mild AVVR, interstage mortality was significantly higher for the MBTS
group (MBTS 18% vs RVPAS 3%; P < .001; OR, 6.7).
However, for subjects with postoperative moderate/severe
AVVR, the overall rate of interstage mortality was similar
between the shunt types (MBTS 20% vs RVPAS 17%;
P ¼ .94; OR, 1.0).
Multivariable analysis. Independent predictors of interstage mortality with adjustment for site determined through
multivariable modeling (adjusted R2 ¼ 0.35) included gestational age less than 37 weeks (OR, 3.9; P ¼ .008), Hispanic ethnicity (OR, 2.6; P ¼ .04), census block poverty
level (P ¼ .003), presence of aortic and mitral atresia
(OR, 2.3; P ¼ .03), MBTS in subjects with postoperative
none/mild AVVR (OR, 9.7; P <.001), and greater number
of post-Norwood complications (OR, 1.2, per complication;
P ¼ .006). With respect to census block poverty levels, subjects in communities with 5.4% to 13% poverty had
a greater risk of interstage mortality compared with subjects
in the more affluent communities (OR, 6.7) and the poorest
communities (OR, 2.5) (Table 2). The exploratory analysis
that included imputed missing values of RVEF, RVESV,
RVEDV, and RV fractional area change showed that these
potential predictors were not independent risk factors of interstage mortality.
DISCUSSION
This is the first multicenter prospective report of interstage
mortality for infants with HLHS and other single right ventricle anomalies undergoing staged repair. The overall interstage
mortality rate of 12% from this large cohort is similar to that
of multiple prior single-center case series.1,3,4,7,8,13
Subjects who had an MBTS were at higher risk for interstage mortality than those with RVPAS. With pulmonary
blood flow occurring only during systole after palliation
with the RVPAS, a higher diastolic pressure and lower pulmonary to systemic flow ratio has been observed.14,15 Although
we are unable to determine the mechanisms of interstage
death in this population, it is possible that the higher
diastolic pressure associated with RVPAS contributes to
improved coronary and systemic perfusion, providing
advantageous hemodynamic stability during periods of
stress such as illness or feeding difficulties. Patients with an
MBTS may have a higher risk for acute shunt thrombosis;
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however, the incidence of shunt thrombosis as a cause for
death was not examined in this analysis.
Although only shunt type was randomized in the SVR
trial, the sample size and prospective data collection allowed for evaluation of other potential predictors of interstage mortality. Previous reports have implicated
anatomic diagnosis, residual or recurrent lesions, arrhythmias, subject specific characteristics, acquired illness,
and, more recently, shunt type as risk factors for interstage
death.1,3-8,13 Although Jonas and colleagues5 found the
combination of aortic atresia with mitral stenosis to be associated with interstage mortality for infants with HLHS,5
other investigators reviewing single-center series have not
found this anatomic variant to be a risk factor.4,16 In the
SVR cohort, only aortic atresia combined with mitral
atresia was independently associated with interstage
mortality. Aortic atresia with mitral stenosis was not
associated with worsened interstage survival for the cohort
as a whole or for either shunt group.
Single-center comparisons of subjects with the RVPAS
versus the MBTS have reported no observable differences
in myocardial performance and ventricular volumes before
the stage II procedure.17,18 Although measurable
differences in RVEF and RVESV indexed for BSA were
observed between shunt types before discharge after the
Norwood procedure, these echocardiographic findings were
not independent risk factors for interstage mortality.
Previous studies have identified postoperative moderate/
severe AVVR as a risk factor for interstage mortality. In the
current analysis, shunt type was a predictor of interstage
mortality when there was mild or no postoperative AVVR.
However, when postoperative AVVR was moderate or
greater, there was no selective benefit of the RVPAS and
both shunt groups had higher mortality rates compared with
subjects with mild or no AVVR and an RVPAS. These data
suggest that the higher interstage mortality risk for the
MBTS is not a consequence of greater AVVR. Moderate to
severe AVVR does increase the risk of interstage mortality,
possibly secondary to the additional volume load and
ineffective ventricular output that can be exacerbated by
conditions that elevate systemic vascular resistance.
We found that gestational age less than 37 weeks was an
independent risk factor for interstage mortality. Given the
high correlation of gestational age with birth weight, it is
not surprising that birth weight was not found to be a separate independent risk factor. In a series comparing outcomes
after cardiac surgery for term and preterm infants, complications of prematurity and postoperative mortality were
common in preterm infants, illustrating the added vulnerability of preterm subjects.19 Other studies have identified
extracardiac anomalies as a risk factor for mortality in subjects with HLHS.20,21 Extracardiac anomalies were not
associated with increased risk in our cohort, but this may
be confounded by a greater tendency for subjects with
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extracardiac malformations to die before hospital
discharge. Furthermore, although use of an RVPAS has
been advocated in the presence of high-risk characteristics,13 our analysis did not demonstrate a particular protective effect of the RVPAS for preterm or low-birth-weight
infants or for infants with extracardiac anomalies. Again,
when considering this finding, it is important to consider
that inclusion in this cohort required survival of the Norwood procedure and discharge from the hospital. Thus, subjects with these risks may be less likely to survive to
hospital discharge after the Norwood procedure. Delivery
at term seems to be an important and likely modifiable
risk factor. This observation is consistent with a large series
in which neonates aged less than 39 weeks with critical congenital heart disease had greater morbidity and interstage
mortality than infants delivered at more than 39 weeks.22
Having a higher number of postoperative complications
correlated with longer length of stay and was an independent
risk factor for interstage mortality. Longer length of stay in
other series of infants with serious congenital heart disease
has been associated with negative outcomes, including early
mortality and lower scores on neurodevelopmental testing.23
Poor interstage growth velocity and malnutrition are common after the Norwood procedure24,25; thus, alternative
feeding methods may be necessary to ensure adequate
nutritional support. However, the best approach to feeding
children after the Norwood procedure remains a challenge
and there is wide variation in practice patterns. Univariate
analysis showed that the absence of oral feeding before
discharge after the Norwood procedure was associated with
interstage mortality, particularly if nasogastric tube feedings
were used rather than a direct gastrostomy tube. Poor
feeding and failure to thrive in infants with congenital heart
disease, specifically single ventricle disease, may be
secondary to several mechanisms, such as decompensated
heart failure, airway abnormalities, or gastrointestinal
dysmotility. Thus, inability to feed orally may be
a surrogate for added vulnerability in the infant with
Norwood physiology. These data suggest that for subjects
who require enteral tube feeding with complete absence of
oral feeding, discharge with a direct gastrostomy tube may
be preferable over a nasal enteral tube. The mechanism for
interstage death in those with a nasogastric tube may
include aspiration due to stenting of the lower esophageal
sphincter, impaired breathing due to nasopharyngeal
obstruction, or vagal response from reflux or gagging
leading to bradycardia-induced arrhythmias.
Interstage mortality was associated with 2 sociodemographic variables: living in a census block with 5.4%
to 13% below the poverty level and Hispanic ethnicity.
Although the finding that participants in census blocks
with lower or higher poverty levels had a lower risk of interstage mortality is not intuitive, it is possible that access to
care was more limited in communities with 5.4% to 13%
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of residents below the poverty level. Although determining
access to care was not within the scope of this study, it may
be valuable to identify high-risk families with reduced access to nearby care to develop a support network and optimize interstage surveillance. Home monitoring with daily
oxygen saturations and weight measurements, and with
increased communication, has been associated with reduced interstage mortality in some series2,4,26 and may be
of particular value when access to pediatric cardiac care is
not readily available. Practices for home monitoring were
not standardized in the SVR trial, and its impact on
interstage mortality was not evaluated in this analysis.
Although this is the largest prospectively followed cohort
of children with HLHS and other single right ventricle
anomalies studied for risk factors for interstage mortality,
there are limitations of our investigation. There was wide
variation in practice throughout the course of this study
across the clinical sites, including inpatient management
for select patients with complicated post-Norwood hospitalization. Many variables evaluated in this study may be
linked, and thus the implications of some practices cannot
be defined. Furthermore, some variables deemed important
even in the multivariable models may be only surrogates for
other unmeasured variables. By adjusting for site and using
bootstrapping, we have tried to minimize bias and maximize reliability.
CONCLUSIONS
We found higher interstage mortality in subjects who received an MBTS. However, RVPAS was only protective for
interstage mortality in those subjects with none/mild AVVR
after the Norwood procedure. Additional independent risk
factors for interstage mortality included gestational age
less than 37 weeks, Hispanic ethnicity, census block with
5.4% to 13% of inhabitants below poverty level, aortic
atresia/mitral atresia, and increased number of postNorwood complications. On the basis of our findings, we
recommend avoiding preterm delivery when possible and
considering close surveillance of infants discharged after
the Norwood procedure with these identified risk factors.
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APPENDIX 1. Pediatric Heart Network Investigators

APPENDIX 1. Continued

National Heart, Lung, and Blood Institute: Gail Pearson, Victoria
Pemberton, Rae-Ellen Kavey,* Mario Stylianou, Marsha Mathis*
Network Chair: University of Texas Southwestern Medical Center,
Lynn Mahony
Data Coordinating Center: New England Research Institutes, Lynn Sleeper
(PI), Sharon Tennstedt (PI), Steven Colan, Lisa Virzi,* Patty Connell,*
Victoria Muratov, Lisa Wruck,* Minmin Lu, Dianne Gallagher, Anne
Devine,* Julie Schonbeck, Thomas Travison,* David F. Teitel
Core Clinical Site Investigators: Children’s Hospital Boston, Jane W.
Newburger (PI), Peter Laussen, Pedro del Nido, Roger Breitbart, Jami
Levine, Ellen McGrath, Carolyn Dunbar-Masterson, John E. Mayer, Jr,
Frank Pigula, Emile A. Bacha, Francis Fynn-Thompson; Children’s
Hospital of New York, Wyman Lai (PI), Beth Printz,* Daphne Hsu,*
William Hellenbrand, Ismee Williams, Ashwin Prakash,* Seema Mital,*
Ralph Mosca,* Darlene Servedio,* Rozelle Corda, Rosalind Korsin,
Mary Nash*; Children’s Hospital of Philadelphia, Victoria L. Vetter
(PI), Sarah Tabbutt,* J. William Gaynor (Study Co-Chair), Chitra
Ravishankar, Thomas Spray, Meryl Cohen, Marisa Nolan, Stephanie
Piacentino, Sandra DiLullo,* Nicole Mirarchi; Cincinnati Children’s
Medical Center, D. Woodrow Benson (PI), Catherine Dent Krawczeski,
Lois Bogenschutz, Teresa Barnard, Michelle Hamstra, Rachel Griffiths,
Kathryn Hogan, Steven Schwartz,* David Nelson, Pirooz Eghtesady*;
North Carolina Consortium: Duke University, East Carolina University,
Wake Forest University, Page A. W. Anderson (PI) – deceased, Jennifer
Li (PI), Wesley Covitz, Kari Crawford,* Michael Hines, James Jaggers,*
Theodore Koutlas, Charlie Sang, Jr, Lori Jo Sutton, Mingfen Xu;
Medical University of South Carolina, J. Philip Saul (PI), Andrew Atz,
Girish Shirali, Scott Bradley, Eric Graham, Teresa Atz, Patricia Infinger;
Primary Children’s Medical Center and the University of Utah, L.
LuAnn Minich (PI), John A. Hawkins, Michael Puchalski, Richard V.
Williams, Peter C. Kouretas, Linda M. Lambert, Marian E. Shearrow,
Jun A. Porter*; Hospital for Sick Children, Brian McCrindle (PI), Joel
Kirsh, Chris Caldarone, Elizabeth Radojewski, Svetlana Khaikin, Susan
McIntyre, Nancy Slater; University of Michigan, Caren S. Goldberg (PI),
Richard G. Ohye (Study Chair), Cheryl Nowak*; Children’s Hospital of
Wisconsin and Medical College of Wisconsin, Nancy S. Ghanayem (PI),
James S. Tweddell, Kathleen A. Mussatto, Michele A. Frommelt, Peter
C. Frommelt, Lisa Young-Borkowski
Auxiliary Sites: Children’s Hospital Los Angeles, Alan Lewis (PI), Vaughn
Starnes, Nancy Pike; The Congenital Heart Institute of Florida, Jeffrey
P. Jacobs (PI), James A. Quintessenza, Paul J. Chai, David S. Cooper, J.
Blaine John, James C. Huhta, Tina Merola, Tracey Grifith; Emory
University, William Mahle (PI), Kirk Kanter, Joel Bond,* Jeryl
Huckaby; Nemours Cardiac Center, Christian Pizarro (PI), Carol
Prospero; Julie Simons, Gina Baffa, Wolfgang A. Radtke; University of
Texas Southwestern Medical Center, Ilana Zeltzer (PI), Tia Tortoriello,*
Deborah McElroy, Deborah Town
Angiography Core Laboratory: Duke University, John Rhodes,
J. Curt Fudge
Echocardiography Core Laboratories: Children’s Hospital of Wisconsin,
Peter Frommelt; Children’s Hospital Boston, Gerald Marx
Genetics Core Laboratory: Children’s Hospital of Philadelphia,
Catherine Stolle
(Continued)

Protocol Review Committee: Michael Artman (Chair), Erle Austin,
Timothy Feltes, Julie Johnson, Thomas Klitzner, Jeffrey Krischer,
G. Paul Matherne
Data and Safety Monitoring Board: John Kugler (Chair), Rae-Ellen
Kavey* (Executive Secretary), David J. Driscoll, Mark Galantowicz,
Sally A. Hunsberger, Thomas J. Knight, Holly Taylor, Catherine L.
Webb*

904

PI, Principal investigator. *No longer at the institution listed.
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APPENDIX TABLE 2. Candidate predictor list

APPENDIX TABLE 2. Continued

Site
Shunt type
Baseline characteristics
Gestational age (wk)
Preterm (gestational age < 37 wk)
Birth weight (kg)
Low birth weight (<2500 g)
Race (white, black, other)
Hispanic
Anatomic diagnosis (HLHS, single right ventricle with systemic outflow,
straddling mitral valve with left ventricle hypoplasia and outflow
obstruction, other)
HLHS (yes/no)
Heterotaxy (yes/no)
Aortic atresia/mitral atresia (yes/no)
Aortic atresia/mitral stenosis (yes/no)
Aortic stenosis/mitral stenosis (yes/no)
Obstructed pulmonary venous return (yes/no)
Age at Norwood (d)
US Census Socioeconomic Index Score
US Census % below poverty level
Norwood hospitalization
Total bypass time (min)
Perfusion strategy during Norwood: DHCA only, RCP only or RCP with
DHCA no > 10 min, RCP and DHCA time > 10 min)
ECMO (yes/no)
Ultrafiltration during (yes/no)
Aortic atresia (yes/no)
Steroids (yes/no)
Trasylol (yes/no)
Alpha-blockade (yes/no)
CPR post-Norwood during hospital stay (yes/no)
Oxygen saturation at discharge post-Norwood (yes/no)
Norwood length of stay
No. of unintended cardiovascular procedures
Balloon dilation, stent placement, or surgical revision of the neo-aorta
(yes/no)
Pulmonary artery reconstruction (yes/no)
Balloon dilation or stenting of the shunt or branch pulmonary arteries
(yes/no)
Shunt revision or crossover (yes/no)
Atrioventricular valve repair (yes/no)
Diaphragm plication (yes/no)
Gastrostomy tube (yes/no)
Pericardial window (yes/no)
Shunt revision (no crossover)
Thoracostomy tube (yes/no)
No. of complications predischarge, post-Norwood
Any serious adverse event (yes/no)
Any oral feeding at discharge (yes/no)
Only oral feeding at discharge (yes/no)
Feeding category (gastrostomy or gastrostomy-jejunal tube, nasal gastric
or nasal jejunal tube, only oral)
Feeding category (no oral, G or GJ tube; no oral, NG or NJ tube; oral,
G or GJ tube; oral, NG or NJ tube; only oral)
No. of discharge medications
(Continued)

Echocardiography pre-Norwood
RVEDV indexed to BSA1.3
RVESV indexed to BSA1.3
RVEF
Atrioventricular valve insufficiency (moderate to severe AVVR) at
pre-Norwood
Ascending aorta diameter (mm)
Echocardiography post-Norwood
Echo Nakata Index
Aortic valve insufficiency (not patent, no regurgitation, regurgitation)
Atrioventricular valve insufficiency at post-Norwood (none/mild vs
moderate/severe).
Right ventricular end-diastolic volume indexed to BSA1.3
Right ventricular end-systolic volume indexed to BSA1.3
RVEF
Right ventricular percent area change
Reversal of pulmonary vein flow (yes/no)
Genetic evaluations (yes at any visit)
Genetic syndrome (yes/no)
Any nonsyndromic abnormality (yes/no)
Genotype (E3/E3, E4/E4, E2/E3, E2/E4, E3/E4)
Site volume and surgeon Norwood volume
Surgeon Norwood experience, based on all screened subjects
(continuous and 4-level categories)
Site volume, based on annual center volume of Norwood procedures
(continuous and 4-level categories)
HLHS, Hypoplastic left heart syndrome; DHCA, deep hypothermic circulatory arrest;
RCP, regional cerebral perfusion; ECMO, extracorporeal membrane oxygenation;
CPR, cardiopulmonary resuscitation; G, gastrostomy, GJ, gastric-jejunal; NG, nasogastric; NJ, nasojejunal; RVEDV, right ventricular end-diastolic volume; BSA, body
surface area; RVESV, right ventricular end-systolic volume; RVEF, right ventricular
ejection fraction; AVVR, atrioventricular valve regurgitation.
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APPENDIX TABLE 3. Univariate comparisons of subjects who were
discharged after Norwood procedure with those who were not
discharged and survived to stage II

Characteristic

CHD

Shunt
RVPAS
MBTS
Norwood hospitalization
Norwood length of
stay (d)
Median (IQR)
Total bypass time (min)
Median (IQR)
Placed on ECMO
No
Yes
Ultrafiltration during CPB
No
Yes
Steroids
No
Yes
CPR post-Norwood
during hospital stay
No
Yes
No. of unintended
cardiovascular
procedures
0
1
2
Balloon dilation or stenting
of the shunt or branch
pulmonary arteries
No
Yes
Shunt revision or crossover
No
Yes
Shunt revision without
crossover
No
Yes
PA reconstruction
No
Yes
Gastrostomy tube
No
Yes
Thoracostomy tube
No
Yes

Discharged
(N ¼ 426)

Not discharged
and survived
P
(N ¼ 22)
value
.52

225 (53)
201 (47)

23 (16-36)

10 (46)
12 (55)

115 (67-147)

130.0 (101.0-163.0) 152.0 (122.0-184.0)
402 (94)
24 (5.6)

<.001
.03
<.001

13 (59)
9 (41)
.02

161 (38)
265 (62)

3 (14)
19 (86)
.005

40 (9.4)
386 (91)

7 (32)
15 (68)
<.001

397 (93)
29 (6.8)

10 (45)
12 (55)
<.001

360 (85)
56 (13)
10 (2.3)

12 (55)
6 (27)
4 (18)
.02

408 (96)
18 (4.2)

18 (82)
4 (18)

378 (89)
48 (11)

16 (73)
6 (27)

.04

.002
411 (96)
15 (3.5)

17 (77)
5 (23)

426 (100)
0 (0.0)

21 (95)
1 (4.5)

357 (84)
69 (16)

12 (55)
10 (45)

.05

.002

.03
404 (95)
22 (5)

18 (82)
4 (18)
(Continued)
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APPENDIX TABLE 3. Continued

Characteristic

Discharged
(N ¼ 426)

Complications and
serious adverse events
No. of complications
Median (IQR)
2.0 (1.0-3.0)
No. of SAEs
Median (IQR)
0.0 (0.0-0.0)
Any SAE
0
362 (85)
1
64 (15)
Feeding at discharge
Any oral feeding?
No
91 (21)
Yes
335 (79)
Only oral feeding?
No
286 (67)
Yes
140 (33)
Feeding category (3 df)
Any oral, other tube
0 (0.0)
Any oral, G or GJ tube
76 (18)
Any oral, NG or NJ tube 210 (49)
Only oral
140 (33)
Feeding category (4 df)
No oral, other tube
0 (0)
No oral, G or GJ tube
55 (13)
No oral, NG or NJ tube
36 (8)
Oral and G or GJ tube
21 (5)
Oral and NG or NJ tube 174 (41)
Only oral
140 (33)
Echocardiography
pre-Norwood
AVVR
None/mild
368 (88)
Moderate/severe
49 (12)
Echocardiography
post-Norwood
Akata Index
Median (IQR)
123.3
(95.5-159.0)
AVVR
None/mild
329 (78)
Moderate/severe
94 (22)
Death during stage II
hospitalization
among subjects
surviving to stage II
No
367 (98)
Yes
9 (2)

Not discharged
and survived
P
(N ¼ 22)
value

6.0 (3.0-15.0)

<.001

1.0 (0.0-2.0)

<.001
<.001

9 (41)
13 (59)
<.001
18 (82)
4 (18)
<.001
22 (100)
0 (0)
<.001
1 (5)
12 (55)
9 (41)
0 (0)
<.001
1 (5)
10 (45)
7 (32)
2 (9)
2 (9)
0 (0)

.04
16 (73)
6 (27)

157.1
(120.4- 223.6)

.006
.003

10 (48)
11 (52)

14 (64)
8 (36)

<.001

With the exception of shunt type, only differences in characteristics between discharged and nondischarged subjects with P < .05 are presented. Fisher exact test
was used to compare subject groups for variables that are dichotomous or categoric.
The Wilcoxon rank-sum test was used to compare subject groups for continuous variables that are skewed. Student 2-sample t test was used for continuous variables that
are not skewed. RVPAS, Right ventricle-to-pulmonary artery shunt; MBTS, modified
Blalock–Taussig shunt; IQR, interquartile range; ECMO, extracorporeal membrane
oxygenation; CPB, cardiopulmonary bypass; CPR, cardiopulmonary resuscitation;
PA, pulmonary artery; SAE, serious adverse event; G, gastrostomy; GJ, gastricjejunal; NG, nasogastric; NJ, nasojejunal; AVVR, atrioventricular valve regurgitation.
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